#HematologyOncology
LightNews LightNews
nationaldaycalendar.com
Sending a massive THANK YOU to some real-life superheroes—pediatric hematology and oncology nurses!🦸‍♀️🦸‍♂️
#PediatricHematologyOncologyNursesDay #NationalDayCalendar
https://nationaldaycalendar.com/celebrations/national-pediatric-hematologyoncology-nurses-day-september-8
September 8, 2026 at 2:12 PM
medpagetoday.com
With some trepidation, a majority of an FDA advisory committee Thursday endorsed the Galleri multicancer early detection blood test.
https://www.medpagetoday.com/hematologyoncology/othercancers/123127
FDA Advisors Recommend Galleri Multicancer Blood Test
Some panelists had reservations about the test's true benefit, however
www.medpagetoday.com
September 24, 2026 at 2:00 PM
medpagetoday.com
Overall cancer mortality rate in the U.S. declined by 35% between 1991 and 2024, according to @theaacr.bsky.social progress report.
https://www.medpagetoday.com/hematologyoncology/othercancers/123111
U.S. Cancer Mortality Declined 35% Since 1991, AACR Report Shows
Group calls for sustained federal investment amid turmoil at NIH and other health agencies
www.medpagetoday.com
September 23, 2026 at 9:25 PM
medpagetoday.com
Human papillomavirus (HPV) vaccination slashed cervical cancer incidence, reduced the risk of precancerous lesions and anogenital warts, and did so without increasing serious side effects, according to two large meta-analyses.
https://www.medpagetoday.com/hematologyoncology/cervicalcancer/118678
HPV Vaccination Tied to Huge Reduction in Cervical Cancer Risk
Two large meta-analyses reassure on safety, efficacy
www.medpagetoday.com
November 30, 2025 at 6:31 PM
medpagetoday.com
A promising combination for multiple myeloma received FDA approval as a second-line therapy.
https://www.medpagetoday.com/hematologyoncology/myeloma/120201
Myeloma Combo With 'Unprecedented' Effect Wins FDA Approval
In second- or later-line setting, combination cut risk of disease progression or death by 83%
www.medpagetoday.com
March 7, 2026 at 1:29 AM
oncodaily.bsky.social
Save the Date: Master Course in Pediatric Oncology – General Principles and Hematology-Oncology
@stjude.bsky.social

oncodaily.com/societies/23...

#Cancer #HematologyOncology #MasterCourse #OncoDaily #Oncology #PediatricOncology #PrincessMáximaCenter #Health #St.Jude #Medicine
Save the Date: Master Course in Pediatric Oncology – General Principles and Hematology-Oncology - OncoDaily
Save the Date: Master Course in Pediatric Oncology – General Principles and Hematology-Oncology / cancer, Hematology Oncology, Master Course, OncoDaily,
oncodaily.com
February 4, 2025 at 5:08 PM
medpagetoday.com
As many as 94% of ultrasound-based papillary thyroid cancer diagnoses represented overdiagnosis, particularly among women, according to a computer modeling study spanning three decades.
https://www.medpagetoday.com/hematologyoncology/othercancers/120015
Reining in Overdiagnosis of Papillary Thyroid Cancer: Easier Said Than Done
Cutting ultrasound referrals for nonpalpable nodules could lead to decreases in incidence
www.medpagetoday.com
February 28, 2026 at 10:18 PM
medpagetoday.com
FDA staff members had no major concerns or questions about the safety, accuracy, risks, or benefits of the Galleri multicancer early detection blood test ahead of an advisors' meeting that will be held Wednesday. https://www.medpagetoday.com/hematologyoncology/othercancers/123089
FDA Staff Find No Major Concerns With Galleri Multicancer Early Detection Test
Comments were noncommittal in agency document released ahead of advisors' meeting
www.medpagetoday.com
September 22, 2026 at 1:42 PM
medpagetoday.com
Women vaccinated against human papillomavirus (HPV) had a significantly lower risk of high-grade vulvovaginal lesions, a large cohort study from Sweden showed.

Read more at: https://www.medpagetoday.com/hematologyoncology/othercancers/119184?trw=no
HPV Vaccine Protection Extends to High-Grade Vulvovaginal Precancers
Risk was reduced by 37-55% in vaccinated versus unvaccinated women in Sweden
www.medpagetoday.com
December 27, 2025 at 8:58 PM
medpagetoday.com
A pooled analysis of randomized trials in colon cancer identified a benchmark representing a "clinically relevant definition of cure," researchers said.
https://www.medpagetoday.com/hematologyoncology/coloncancer/117760
What Constitutes 'Cure' in Colon Cancer? Researchers Propose a New Definition
Defining cure in stage II and III colon cancer has been challenging, researchers say
www.medpagetoday.com
October 5, 2025 at 5:10 PM
cudeptofmedicine.bsky.social
Step into the life of Dr. Aaron Lee, a second-year hematology-oncology fellow! From patient care to research, here’s a peek into his week. 🤗🩺🏔️ #Fellowship #HematologyOncology #DIL #Medsky
March 7, 2025 at 7:29 PM
medpagetoday.com
More than two dozen bacteria and fungi in the mouth may be linked to an increased risk of pancreas cancer, according to an analysis of two large cohorts.
https://www.medpagetoday.com/hematologyoncology/othercancers/117531
Mouth Microbes Linked to Pancreas Cancer Risk
A microbial risk score could help identify people at greater risk
www.medpagetoday.com
September 18, 2025 at 7:30 PM
medpagetoday.com
The FDA approved the oral fibroblast growth factor receptor 2 inhibitor lirafugratinib (Lyrfigtu) for adults with previously treated cholangiocarcinoma with FGFR2 fusion or other rearrangements, the agency announced Wednesday.
https://www.medpagetoday.com/hematologyoncology/othercancers/123137
FDA Approves New Option for Previously Treated Bile Duct Cancer
Trial of lirafugratinib showed responses in almost half of patients, with good durability
www.medpagetoday.com
September 25, 2026 at 6:06 PM
medpagetoday.com
Women who used progestogen contraceptives had a significantly increased risk of meningioma, including oral and injectable progestogen formulations and IUDs, a large Danish study showed.
https://www.medpagetoday.com/hematologyoncology/braincancer/122030
New Evidence Links Progestogen Contraceptives to Brain Cancer Risk
Danish study expands association to include injectable and oral medications, IUDs
www.medpagetoday.com
July 2, 2026 at 7:40 PM
medpagetoday.com
Oncology specialists should inform patients about a risk of serious toxicity related to DPD deficiency and should test for DPYD variants before starting treatment with capecitabine (Xeloda) and fluorouracil, the FDA announced.
https://www.medpagetoday.com/hematologyoncology/othercancers/119774
FDA Calls for Testing Before Treatment With Widely Used Chemotherapies
Notice highlights risks of DPD deficiency with capecitabine, fluorouracil
www.medpagetoday.com
February 8, 2026 at 12:39 AM
medpagetoday.com
Women who continued screening mammography into their 80s had earlier-stage, lower-risk breast cancers and better outcomes as compared with women who did not have a recent mammogram, a retrospective record review showed.
https://www.medpagetoday.com/hematologyoncology/breastcancer/117640
September 28, 2025 at 10:16 PM
medpagetoday.com
Older age should not discourage healthy women with a genetic risk for ovarian cancer from considering risk-reducing bilateral salpingo-oophorectomy, investigators in a study of BRCA carriers concluded.
https://www.medpagetoday.com/hematologyoncology/ovariancancer/123123
Gauging Benefits of Risk-Reducing Surgery for BRCA-Related Ovarian Cancer
For at-risk women who delay surgery, risk remains substantial at 50, especially with BRCA1
www.medpagetoday.com
September 24, 2026 at 6:33 PM
medpagetoday.com
A history of induced abortion or miscarriage was not associated with an increased risk of breast cancer, according to a Finnish case-control study.

Read more at: https://www.medpagetoday.com/hematologyoncology/breastcancer/119841
Does Abortion or Miscarriage Contribute to Breast Cancer Risk?
The possibility has raised concerns, led to the spread of misinformation
www.medpagetoday.com
February 12, 2026 at 10:38 PM
medpagetoday.com
Patients with advanced lung cancer had better survival outcomes when they received immunochemotherapy earlier in the day, a randomized trial showed.
https://www.medpagetoday.com/hematologyoncology/lungcancer/119696
Time of Day Matters for Immunochemotherapy in Lung Cancer
This is a 'landmark study' for cancer immunotherapy and circadian medicine, researcher says
www.medpagetoday.com
February 5, 2026 at 4:16 PM
binaytara.bsky.social
🎓Calling all 2025 Medical Fellows! Starting your hematology-oncology fellowship? Binaytara offers FREE resources to enhance your potential: buff.ly/LGjy6bY #MedicalFellows #HematologyOncology #FreeCME #MedicalEducation #Binaytara #Fellowship2025
August 13, 2025 at 7:03 PM
hemehub.bsky.social
🩸🔬 Today’s questions!

Swipe to see the answers and their explanations!

#MultipleMyeloma #MajesTEC3 #Teclistamab #BispecificAntibodies #StepUpDosing #Immunotherapy #IVIG #HematologyOncology #Oncology #MedEd #ClinicalTrials #HEMEHUB
February 28, 2026 at 11:45 PM
medpagetoday.com
Setidegrasib showed promising efficacy in patients with previously treated advanced KRAS G12D-mutated pancreatic ductal adenocarcinoma or non-small cell lung cancer, results from a phase I trial suggested.
https://www.medpagetoday.com/hematologyoncology/othercancers/120495
First-in-Class KRAS-Degrader Promising in Pancreatic, Lung Cancers
'There is a clear unmet need for therapies,' researcher says
www.medpagetoday.com
March 26, 2026 at 6:07 PM
medpagetoday.com
Adding the BCL2 inhibitor venetoclax (Venclexta) to chemoimmunotherapy led to worse outcomes and excess mortality in patients with newly diagnosed double-hit lymphoma, phase II results from a randomized trial showed. https://www.medpagetoday.com/hematologyoncology/lymphoma/122957
Study Warns on Venetoclax in Double-Hit Lymphoma
Excess deaths seen in trial combining the BCL2 inhibitor with intensive initial regimen
www.medpagetoday.com
September 15, 2026 at 2:11 AM
medpagetoday.com
One dose of a bivalent or nonavalent human papillomavirus (HPV) vaccine was protective against HPV16 and HPV18 infections, and showed noninferiority to two doses, the randomized ESCUDDO trial found.

Read more at: https://www.medpagetoday.com/hematologyoncology/cervicalcancer/118816?trw=no
One Dose of HPV Vaccine Just as Effective as Two, Trial Finds
Results support WHO recommendation for single-dose vaccination to achieve higher coverage
www.medpagetoday.com
December 6, 2025 at 11:53 PM
medpagetoday.com
The FDA approved trastuzumab deruxtecan (T-DXd; Enhertu) in combination with pertuzumab (Perjeta) for the first-line treatment of adults with unresectable or metastatic HER2-positive breast cancer.
https://www.medpagetoday.com/hematologyoncology/breastcancer/119027
Blockbuster Drug Lands First-Line Indication for HER2-Positive Breast Cancer
T-DXd approved in combination with pertuzumab for newly diagnosed unresectable/metastatic disease
www.medpagetoday.com
December 17, 2025 at 12:10 AM